Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Praxis Precision Medicines (NASDAQ: PRAX) will report fourth quarter and full year 2025 financial results and provide a corporate update before markets open on February 19, 2026 at 8:00 am ET.
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX) will report fourth quarter and full year 2025 financial results and provide a corporate update before markets open on February 19, 2026 at 8:00 am ET. The company will host a conference call and live webcast; replays will be available on the Events & Presentations page for ~90 days.
Management will present at Guggenheim Biotech Summit on Feb 11, 2026 and TD Cowen Health Care Conference on Mar 2, 2026, with live webcasts and subsequent replays.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PRAX
On Feb 10, the first trading day after this news, PRAX closed 0.29% above the previous close.
Data tracked by StockTitan Argus for the Feb 10 session.
Key Figures
- Earnings date
- February 19, 2026
- Planned Q4 and full-year 2025 results release
- Earnings call time
- 8:00 am ET
- Conference call and webcast on February 19, 2026
- Conference date
- February 11, 2026
- Guggenheim Emerging Outlook: Biotech Summit 2026 presentation
- Conference time
- 1:00 pm ET
- Guggenheim Summit corporate presentation slot
- Conference date
- March 2, 2026
- TD Cowen 46th Annual Health Care Conference presentation
- Conference time
- 11:50 am ET
- TD Cowen corporate presentation slot
- Replay availability
- 90 days
- Webcast replays on company website after each event
Historical Context
-
New employee inducement RSU awards under 2024 Inducement Plan.
-
Appointment of global epilepsy leader as Head of Clinical Strategy.
-
Pivotal 2025 recap, 2026 priorities, NDAs and large capital raise.
-
Small RSU awards to new hires under Nasdaq inducement rules.
-
New directors and senior promotions to support late-stage growth.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026.
The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com.
Praxis management will also be present at the following two upcoming investor conferences:
- Guggenheim Emerging Outlook: Biotech Summit 2026: a corporate presentation will take place on February 11 at 1pm ET at the Lotte New York Palace Hotel in New York City, NY. A live webcast will be available through link.
- TD Cowen 46th Annual Health Care Conference: a corporate presentation will take place on March 2 at 11:50am ET at the Boston Marriott Copley Place Hotel in Boston, MA. A live webcast will be available through link.
Replays will be available on Praxis’ Events & Presentations page of the company’s website after each event for approximately 90 days.
About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.